Coherus Biosciences
2 known investors
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.
BiotechHealthtechMedical Devices
Investors · 2
In the news
- Coherus, Zumutor start Phase 1 ZM008-LOQTORZI trial | CHRS Stock Newsstocktitan.net · 2026
- Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook By Investing.cominvesting.com · 2026
- Coherus Biosciences Signals Confident Oncology Earnings Outlook - TipRanks.comtipranks.com · 2026
- BioCentury - Coherus raises $100M in note dealbiocentury.com · 2016
- BioCentury - Coherus raises $120M in follow-onbiocentury.com · 2015